Miconazole

Miconazole (R18134) is an imidazole antifungal agent that is used topically and by intravenous infusion.

Miconazole nitrate (R18134 nitrate), an imidazole antifungal agent, selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes.

Pramiconazole (R126638) is an orally available antifungal compound.Pramiconazole is a candidate for the treatment of dermatophytes and cutaneous yeast infections in seborrheic dermatitis.

Antifungal agent 54 (compound A05) serves as a potent inhibitor against Fluconazole-resistant strains, outperforming Miconazole in efficacy. It exhibits considerable activity against Candida albicans, with minimum inhibitory concentration (MIC) values ranging from 0.25-1 μg/mL [1].

Fluconazole (hydrate) is a triazole antifungal agent used for the oral treatment and prevention of both superficial and systemic fungal infections, including but not limited to balanitis, various Candida infections, Cryptococcus infections, dermatomycosis, and fungal infections of the respiratory and urinary tracts. As the hydrate salt form of fluconazole, it exhibits antifungal activity by inhibiting the growth and development of pathogenic fungi, such as Candida species, at minimal inhibitory concentrations often exceeding 100 mg/l. Notably, it disrupts the branching and hyphal formation in C. albicans at concentrations as low as 0.3 mg/l, indicating its potency in comparison to other antifungals like miconazole and ketoconazole which require 100-fold lower concentrations to be effective. Clinical studies have not linked oral fluconazole with a significant increase in the risk of most birth defects, although there may be an associated risk of tetralogy of Fallot. Its efficacy against Cryptococcus gattii in koalas suggests it may be ineffective as a sole therapeutic agent at a dosage of 10 mg/kg orally every 12 h. Toxicity symptoms from overdose can include hallucinations and paranoid behavior.

Antifungal agent 55 (Compound A07) effectively inhibits Fluconazole-resistant strains of Candida albicans, demonstrating greater efficacy than Miconazole. It exhibits minimum inhibitory concentrations (MIC) values ranging from 0.25-1 μg/mL [1].

Antifungal agent 56 (compound A09) is a potent antifungal agent, demonstrating superior efficacy against Fluconazole-resistant strains and outperforming Miconazole. It effectively inhibits Candida albicans strains, with minimal inhibitory concentration (MIC) values ranging from 0.03 to 0.25 μg/mL [1].

Antifungal Agent 57 (Compound A19) demonstrates potent efficacy against Fluconazole-resistant strains, outperforming Miconazole. It effectively inhibits Candida albicans strains, exhibiting minimum inhibitory concentrations (MIC) ranging from 0.5 to 2 μg/mL [1].

Eberconazole, a dichlorinated imidazole derivative, exhibits antifungal activity and outperforms Clotrimazole, Ketoconazole, and Miconazole in efficacy. It holds promise for dermatophytoses research through topical administration.

Eberconazole Nitrate (Ebernet) is an azole antifungal agent and broad-spectrum imidazole derivative.

Antifungal agent 58 (compound A21) exhibits high potency against Fluconazole-resistant strains and outperforms Miconazole in effectiveness. It inhibits Candida albicans strains with minimum inhibitory concentration (MIC) values ranging from 0.06 to 8 μg/mL [1].